Flumazenil nasal spray as well as preparation method and application thereof
By developing flumasini nasal spray, using components such as benzyl alcohol, propylene glycol and polyethylene glycol 400, combined with acid-base regulation, the problem of inconvenience in intravenous injection is solved, and the rapid, safe and convenient flumasini is achieved Central nervous system administration meets the emergency reversal needs of patients with benzodiazepine poisoning.
Patent Information
- Application Number
- CN202411261971.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-10
- Publication Date
- 2024-12-06
AI Technical Summary
The existing intravenous injection methods of flumasinib have problems such as pain, irritation and inconvenience in use, which is difficult to meet the emergency rescue needs of patients with benzodiazepine poisoning.
A flumasini nasal spray was developed, containing flumasini, benzyl alcohol, propylene glycol and polyethylene glycol 400. The pH value is adjusted by acid-base regulators, combined with preservatives and stabilizers, and a simple preparation method is adopted. , forming a colorless clear spray.
It achieves efficient dissolution of flumasinib, improves the stability of the preparation, bypasses the blood-brain barrier through nasal administration, and directly reaches the central nervous system, taking effect quickly, making it easy for patients to use on their own, and is safe, convenient and economical.
Smart Images

Figure BDA0005035974290000131 
Figure BDA0005035974290000141 
Figure BDA0005035974290000142
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biomedicine, and specifically relates to a flumazenil nasal spray, a preparation method thereof and an application thereof. Background Art
[0002] People experience nervous and mental tension due to various pressures, which can cause fatigue, difficulty concentrating, anxiety, irritability, decreased sleep quality, insomnia and other symptoms. This type of drug is used for sedation and treatment of acute insomnia and has achieved good therapeutic effects, but long-term use may cause adverse reactions such as drowsiness, excessive sedation and poisoning.
[0003] Flumazenil is a benzodiazepine Class-specific receptor antagonists and benzodiazepines Antidotes for drugs of this class and drugs for the treatment of central nervous system diseases, mainly through Flumazenil injection (intravenous injection, specification: 0.1 mg / mL) is clinically used to reverse the sedative effect of benzodiazepines in adults or children aged 1 year and above. Flumazenil can be used to induce sedation, hypnosis and to relieve poisoning caused by overdose. However, intravenous administration has the disadvantages of requiring professional personnel to inject, causing injection pain and irritation, inconvenience in use, and poor patient compliance. Therefore, it is necessary to develop a more efficient and safe new flumazenil formulation to facilitate the use of benzodiazepines. It can provide rescue and self-rescue for patients with central sedation, hypnosis and overdose caused by these drugs, and meet clinical needs. Summary of the invention
[0004] The object of the present invention is to provide a flumazenil nasal spray, which contains 0.1-1% of flumazenil, 1-20% of benzyl alcohol, 0-20% of propylene glycol and 0-20% of polyethylene glycol 400 in terms of mass volume ratio.
[0005] In the preferred technical solution of the present invention, the nasal spray contains 0.1-0.5% flumazenil, 4-10% benzyl alcohol, 0-10% propylene glycol and 10-20% polyethylene glycol 400 in terms of mass volume ratio.
[0006] In the preferred technical solution of the present invention, the nasal spray contains 0.1-0.5% flumazenil, 4-10% benzyl alcohol, 5-10% propylene glycol and 10-20% polyethylene glycol 400 in terms of mass volume ratio.
[0007] In the preferred technical solution of the present invention, the mass ratio of benzyl alcohol:propylene glycol:polyethylene glycol 400 in the nasal spray is 1-20:0-20:0-20, preferably 4-10:0-10:10-20, and more preferably 4-10:5-10:10-20.
[0008] In a preferred technical solution of the present invention, the nasal spray further contains an acid-base regulator.
[0009] In the preferred technical scheme of the present invention, the acid-base regulator is selected from any one of hydrochloric acid, sodium hydroxide, citric acid, sodium citrate, malate, lactic acid, sodium lactate, potassium lactate, triethanolamine, potassium carbonate, potassium bicarbonate, sodium carbonate, sodium bicarbonate, phosphate, sodium phosphate, disodium hydrogen phosphate, sodium dihydrogen phosphate, potassium phosphate, dipotassium hydrogen phosphate, potassium dihydrogen phosphate, HAc (acetic acid) / NaAc (sodium acetate), citric acid / sodium citrate, NaHCO3 / H2CO3, Na2HPO4 / NaH2PO4 or a combination thereof.
[0010] In a preferred technical solution of the present invention, the pH of the nasal spray is 3.5-6.0, preferably pH 4.0-5.5.
[0011] In the preferred technical solution of the present invention, the nasal spray contains 0.2% flumazenil, 5% benzyl alcohol and 15% polyethylene glycol 400 in terms of mass volume ratio.
[0012] In the preferred technical solution of the present invention, the nasal spray contains 0.2% flumazenil, 5% benzyl alcohol and 10% polyethylene glycol 400 in terms of mass volume ratio.
[0013] In the preferred technical solution of the present invention, the nasal spray contains 0.1% flumazenil, 10% benzyl alcohol, 10% propylene glycol and 20% polyethylene glycol 400 in terms of mass volume ratio.
[0014] In the preferred technical solution of the present invention, the nasal spray contains 0.2% flumazenil, 10% benzyl alcohol, 10% propylene glycol and 20% polyethylene glycol 400 in terms of mass volume ratio.
[0015] In the preferred technical solution of the present invention, the nasal spray contains 0.3% flumazenil, 10% benzyl alcohol, 10% propylene glycol and 20% polyethylene glycol 400 in terms of mass volume ratio.
[0016] In the preferred technical solution of the present invention, the nasal spray contains 0.2% flumazenil, 5% benzyl alcohol, 10% propylene glycol and 15% polyethylene glycol 400, calculated by mass volume ratio.
[0017] In the preferred technical solution of the present invention, the nasal spray contains 0.2% flumazenil, 4.5% benzyl alcohol, 5% propylene glycol and 20% polyethylene glycol 400 in terms of mass volume ratio.
[0018] In the preferred technical solution of the present invention, the nasal spray contains 0.2% flumazenil, 4.25% benzyl alcohol, 5% propylene glycol and 20% polyethylene glycol 400 in terms of mass volume ratio.
[0019] In the preferred technical solution of the present invention, the nasal spray contains 0.2% flumazenil, 5% benzyl alcohol, 5% propylene glycol and 20% polyethylene glycol 400 in terms of mass volume ratio.
[0020] In the preferred technical solution of the present invention, the nasal spray contains 0.2% flumazenil, 5.5% benzyl alcohol, 5% propylene glycol and 20% polyethylene glycol 400 in terms of mass volume ratio.
[0021] In the preferred technical solution of the present invention, the nasal spray contains 0.1% flumazenil and 4% benzyl alcohol in terms of mass volume ratio.
[0022] In a preferred technical solution of the present invention, the nasal spray optionally contains a preservative.
[0023] In the preferred technical scheme of the present invention, the preservative is selected from any one of benzalkonium bromide, benzoic acid, sodium benzoate, methylparaben, ethylparaben, propylparaben, butylparaben, sorbic acid, ethanol, glycerol, phenol, cresol, and chlorobutanol, or a combination thereof.
[0024] In a preferred technical solution of the present invention, the preservative contained in the nasal spray is 0-0.05%, preferably 0.01-0.02%.
[0025] In a preferred technical solution of the present invention, the nasal spray optionally contains a stabilizer.
[0026] In the preferred technical solution of the present invention, the stabilizer is selected from any one of disodium edetate, ethylene glycol tetraacetic acid, EDTA or a combination thereof.
[0027] In the preferred technical solution of the present invention, the nasal spray contains 0-0.5% of the stabilizer, preferably 0.1-0.3%.
[0028] In a preferred technical solution of the present invention, the nasal spray optionally contains an absorption enhancer.
[0029] In the preferred technical scheme of the present invention, the absorption enhancer is selected from any one of dodecyl maltose (DDM), tetradecyl maltoside (TDM), polyethylene glycol-15-hydroxystearate (HS-15), hydroxypropyl-B-cyclodextrin (HP-B-CD), cyclodextrin or a combination thereof.
[0030] In the preferred technical solution of the present invention, the absorption enhancer contained in the nasal spray is 0-0.5%, preferably 0.1-0.4%.
[0031] In the preferred technical solution of the present invention, the preparation method of the flumazenil nasal spray is selected from any one of method 1 or method 2:
[0032] Method 1: Weigh the required amount of benzyl alcohol, propylene glycol and polyethylene glycol 400, mix them evenly, then add the required amount of flumazenil, and after it is completely dissolved, add water to 60-90% of the spray, mix evenly, adjust the pH of the system to 3.5-6.0 with an acid-base regulator, and add water to the fixed volume to obtain the product;
[0033] Method 2: Weigh the required amount of benzyl alcohol, propylene glycol and polyethylene glycol 400, mix them evenly, add water to 60-90% of the spray, mix them evenly, then add the required amount of flumazenil, stir until completely dissolved, adjust the system pH to 3.5-6.0 with an acid-base regulator, add water to make up to volume, and you have it.
[0034] In a preferred technical solution of the present invention, water is added to 65-85%, preferably 70-80%, of the spray in method 1 or method 2.
[0035] In the preferred technical solution of the present invention, the dissolution temperature of flumazenil in method 1 or method 2 is 15°C-50°C, preferably 20°C-40°C.
[0036] Another object of the present invention is to provide a method for preparing a flumazenil nasal spray, wherein the nasal spray contains 0.1-1% flumazenil, 1-20% benzyl alcohol, 0-20% propylene glycol and 0-20% polyethylene glycol 400 in a mass-to-volume ratio, and the preparation method of the flumazenil nasal spray is selected from any one of method 1 or method 2:
[0037] Method 1: Weigh the required amount of benzyl alcohol, propylene glycol and polyethylene glycol 400, mix them evenly, then add the required amount of flumazenil, and after it is completely dissolved, add water to 60-90% of the spray, mix evenly, adjust the pH of the system to 3.5-6.0 with an acid-base regulator, and add water to the fixed volume to obtain the product;
[0038] Method 2: Weigh the required amount of benzyl alcohol, propylene glycol and polyethylene glycol 400, mix them evenly, add water to 60-90% of the spray, mix them evenly, then add the required amount of flumazenil, stir until completely dissolved, adjust the system pH to 3.5-6.0 with an acid-base regulator, add water to make up to volume, and you have it.
[0039] In a preferred technical solution of the present invention, water is added to 65-85%, preferably 70-80%, of the spray in method 1 or method 2.
[0040] In the preferred technical solution of the present invention, the dissolution temperature of flumazenil in method 1 or method 2 is 15°C-50°C, preferably 20°C-40°C.
[0041] In the preferred technical solution of the present invention, the nasal spray contains 0.1-0.5% flumazenil, 4-10% benzyl alcohol, 0-10% propylene glycol and 10-20% polyethylene glycol 400 in terms of mass volume ratio.
[0042] In the preferred technical solution of the present invention, the nasal spray contains 0.1-0.5% flumazenil, 4-10% benzyl alcohol, 5-10% propylene glycol and 10-20% polyethylene glycol 400 in terms of mass volume ratio.
[0043] In the preferred technical solution of the present invention, the mass ratio of benzyl alcohol:propylene glycol:polyethylene glycol 400 in the nasal spray is 1-20:0-20:0-20, preferably 4-10:0-10:10-20, and more preferably 4-10:5-10:10-20.
[0044] In a preferred technical solution of the present invention, the nasal spray further contains an acid-base regulator.
[0045] In the preferred technical scheme of the present invention, the acid-base regulator is selected from any one of hydrochloric acid, sodium hydroxide, citric acid, sodium citrate, malate, lactic acid, sodium lactate, potassium lactate, triethanolamine, potassium carbonate, potassium bicarbonate, sodium carbonate, sodium bicarbonate, phosphate, sodium phosphate, disodium hydrogen phosphate, sodium dihydrogen phosphate, potassium phosphate, dipotassium hydrogen phosphate, potassium dihydrogen phosphate, HAc (acetic acid) / NaAc (sodium acetate), citric acid / sodium citrate, NaHCO3 / H2CO3, Na2HPO4 / NaH2PO4 or a combination thereof.
[0046] In a preferred technical solution of the present invention, the pH of the nasal spray is 3.5-6.0, preferably pH 4.0-5.5.
[0047] In the preferred technical solution of the present invention, the nasal spray contains 0.1% flumazenil and 4% benzyl alcohol in terms of mass volume ratio.
[0048] In the preferred technical solution of the present invention, the nasal spray contains 0.2% flumazenil, 5% benzyl alcohol and 15% polyethylene glycol 400 in terms of mass volume ratio.
[0049] In the preferred technical solution of the present invention, the nasal spray contains 0.2% flumazenil, 5% benzyl alcohol and 10% polyethylene glycol 400 in terms of mass volume ratio.
[0050] In the preferred technical solution of the present invention, the nasal spray contains 0.1% flumazenil, 10% benzyl alcohol, 10% propylene glycol and 20% polyethylene glycol 400 in terms of mass volume ratio.
[0051] In the preferred technical solution of the present invention, the nasal spray contains 0.2% flumazenil, 10% benzyl alcohol, 10% propylene glycol and 20% polyethylene glycol 400 in terms of mass volume ratio.
[0052] In the preferred technical solution of the present invention, the nasal spray contains 0.3% flumazenil, 10% benzyl alcohol, 10% propylene glycol and 20% polyethylene glycol 400 in terms of mass volume ratio.
[0053] In the preferred technical solution of the present invention, the nasal spray contains 0.2% flumazenil, 5% benzyl alcohol, 10% propylene glycol and 15% polyethylene glycol 400, calculated by mass volume ratio.
[0054] In the preferred technical solution of the present invention, the nasal spray contains 0.2% flumazenil, 4.5% benzyl alcohol, 5% propylene glycol and 20% polyethylene glycol 400 in terms of mass volume ratio.
[0055] In the preferred technical solution of the present invention, the nasal spray contains 0.2% flumazenil, 4.25% benzyl alcohol, 5% propylene glycol and 20% polyethylene glycol 400 in terms of mass volume ratio.
[0056] In the preferred technical solution of the present invention, the nasal spray contains 0.2% flumazenil, 5% benzyl alcohol, 5% propylene glycol and 20% polyethylene glycol 400 in terms of mass volume ratio.
[0057] In the preferred technical solution of the present invention, the nasal spray contains 0.2% flumazenil, 5.5% benzyl alcohol, 5% propylene glycol and 20% polyethylene glycol 400 in terms of mass volume ratio.
[0058] In the preferred technical solution of the present invention, the nasal spray contains 0.1% flumazenil and 4% benzyl alcohol in terms of mass volume ratio.
[0059] In a preferred technical solution of the present invention, the nasal spray optionally contains a preservative.
[0060] In the preferred technical scheme of the present invention, the preservative is selected from any one of benzalkonium bromide, benzoic acid, sodium benzoate, methylparaben, ethylparaben, propylparaben, butylparaben, sorbic acid, ethanol, glycerol, phenol, cresol, and chlorobutanol, or a combination thereof.
[0061] In a preferred technical solution of the present invention, the preservative contained in the nasal spray is 0-0.05%, preferably 0.01-0.02%.
[0062] In a preferred technical solution of the present invention, the nasal spray optionally contains a stabilizer.
[0063] In the preferred technical solution of the present invention, the stabilizer is selected from any one of disodium edetate, ethylene glycol tetraacetic acid, EDTA or a combination thereof.
[0064] In the preferred technical solution of the present invention, the nasal spray contains 0-0.5% of the stabilizer, preferably 0.1-0.3%.
[0065] In a preferred technical solution of the present invention, the nasal spray optionally contains an absorption enhancer.
[0066] In the preferred technical scheme of the present invention, the absorption enhancer is selected from any one of dodecyl maltose (DDM), tetradecyl maltoside (TDM), polyethylene glycol-15-hydroxystearate (HS-15), hydroxypropyl-B-cyclodextrin (HP-B-CD), cyclodextrin or a combination thereof.
[0067] In the preferred technical solution of the present invention, the absorption enhancer contained in the nasal spray is 0-0.5%, preferably 0.1-0.4%.
[0068] Another object of the present invention is to provide a flumazenil nasal spray for use in the preparation of a drug for reversing benzodiazepines in adults or children aged 1 year and above. Application of drugs in the treatment of central nervous system sedation, hypnosis and overdose poisoning caused by these drugs.
[0069] The flumazenil nasal spray of the present invention is selected according to the patient's age, gender, medication and condition (sedation degree and time, hypnosis degree and time, poisoning degree and time, etc.).
[0070] Unless otherwise specified, the present invention adopts high performance liquid chromatography to efficiently separate and detect flumazenil, unknown impurity 1 and total impurity content in the flumazenil nasal spray of the present invention (Table 1-2).
[0071] Table 1 Content determination method
[0072] Chromatographic columns COSMOSIL C18,5μm,4.6×250mm Mobile phase 0.1% citric acid: acetonitrile: tetrahydrofuran = 77:18:5 Detection wavelength 230nm Flow rate 0.8mL / min Column temperature 30℃ Injection volume 20μL Run time 25min
[0073] Table 2 Impurity determination method
[0074] Chromatographic columns COSMOSIL C18,5μm,4.6×250mm Mobile phase 0.1% citric acid: acetonitrile: tetrahydrofuran = 77:18:5 Detection wavelength 230nm Flow rate 0.8mL / min Column temperature 30℃ Injection volume 20μL Run time 50min
[0075] Compared with the prior art, the present invention has the following beneficial effects:
[0076] 1. The present invention scientifically screens and optimizes the components (such as benzyl alcohol, propylene glycol, polyethylene glycol 400, etc.) and proportions of flumazenil nasal spray, effectively solves the problem of flumazenil dissolution, realizes high-concentration dissolution of flumazenil, avoids drug precipitation, and improves the stability of the preparation. The blood-brain barrier is the biggest obstacle to the absorption of drugs for treating central nervous system diseases. The present invention improves flumazenil injection into a nasal spray, which can bypass the blood-brain barrier by utilizing the physiological structure of the nasal cavity, the nasal mucosa and its abundant blood vessels, and directly reach the brain diseases of central nervous system diseases. It also makes full use of the abundant blood vessels under the nasal mucosa to improve the absorption of drugs, realize nasal brain targeting of central nervous system administration, and improve the blood-brain barrier passage rate of drugs. It has a fast onset of action and is easy to use for reversing the benzodiazepine-induced brain damage in adults or children aged 1 year and above. The flumazenil nasal spray of the present invention has the advantages of safety, effectiveness, high bioavailability, convenient use, better cost, economical use, and good patient compliance.
[0077] 2. The preparation method of the flumazenil nasal spray of the present invention has the advantages of simple operation, high production efficiency, green environmental protection, and easy industrial production. BRIEF DESCRIPTION OF THE DRAWINGS
[0078] Figure 1 The irritation effect of the flumazenil nasal spray of the present invention on the nasal mucosa of rats was investigated. DETAILED DESCRIPTION
[0079] The above contents of the present invention are further described in detail below by way of examples. However, this should not be understood as the scope of the above subject matter of the present invention being limited to the following examples. All technologies implemented based on the above contents of the present invention belong to the scope of the present invention. The following examples further describe the beneficial effects of the present invention, and the examples are only for illustrative purposes and do not limit the scope of the present invention. At the same time, obvious changes and modifications made by ordinary technicians in the field according to the present invention are also included in the scope of the present invention.
[0080] Example 1 Preparation of flumazenil nasal spray of the present invention
[0081] Flumazenil nasal spray composition:
[0082] Components Dosage(g) Flumazenil 1.0 Benzyl alcohol 100.0 Propylene glycol 100.0 Polyethylene glycol 400 200.0
[0083] The preparation of flumazenil nasal spray comprises the following steps:
[0084] After uniformly mixing the required amount of benzyl alcohol, propylene glycol, and polyethylene glycol 400, add the required amount of flumazenil, stir until dissolved, add 480 ml of water, adjust the pH of the spray to 4.0 with an appropriate amount of citric acid / sodium citrate, add water to make the volume to 1000 ml, and prepare a colorless and clear flumazenil nasal spray.
[0085] Example 2 Preparation of flumazenil nasal spray of the present invention
[0086] Flumazenil nasal spray composition:
[0087] Components Dosage(g) Flumazenil 2.0 Benzyl alcohol 100.0 Propylene glycol 100.0 Polyethylene glycol 400 200.0
[0088] The preparation of flumazenil nasal spray comprises the following steps:
[0089] After uniformly mixing the required amount of benzyl alcohol, propylene glycol, and polyethylene glycol 400, add the required amount of flumazenil, stir until dissolved, add 480 ml of water, adjust the pH of the spray to 4.5 with an appropriate amount of citric acid / sodium citrate, add water to make the volume to 1000 ml, and prepare a colorless and clear flumazenil nasal spray.
[0090] Example 3 Preparation of flumazenil nasal spray of the present invention
[0091] Flumazenil nasal spray composition:
[0092] Components Dosage(g) Flumazenil 3.0 Benzyl alcohol 100.0 Propylene glycol 100.0 Polyethylene glycol 400 200.0
[0093] The preparation of flumazenil nasal spray comprises the following steps:
[0094] After uniformly mixing the required amount of benzyl alcohol, propylene glycol, and polyethylene glycol 400, add the required amount of flumazenil, stir until dissolved, add 480 ml of water, adjust the pH of the spray to 4.5 with an appropriate amount of citric acid / sodium citrate, add water to make the volume to 1000 ml, and prepare a colorless and clear flumazenil nasal spray.
[0095] Example 4 Preparation of flumazenil nasal spray of the present invention
[0096] Flumazenil nasal spray composition:
[0097] Components Dosage(g) Flumazenil 2.0 Benzyl alcohol 50.0 Polyethylene glycol 400 150.0
[0098] The preparation of flumazenil nasal spray comprises the following steps:
[0099] After uniformly mixing the required amount of benzyl alcohol and polyethylene glycol 400, add the required amount of flumazenil, stir until dissolved, add 650 ml of water, adjust the pH of the spray to 4.5 with an appropriate amount of citric acid / sodium citrate, add water to make the volume to 1000 ml, and prepare a colorless and clear flumazenil nasal spray.
[0100] Example 5 Preparation of flumazenil nasal spray of the present invention
[0101] Flumazenil nasal spray composition:
[0102] Components Dosage(g) Flumazenil 2.0 Benzyl alcohol 50.0 Propylene glycol 100.0 Polyethylene glycol 400 150.0
[0103] The preparation of flumazenil nasal spray comprises the following steps:
[0104] After uniformly mixing the required amount of benzyl alcohol, propylene glycol, and polyethylene glycol 400, add the required amount of flumazenil, stir until dissolved, add 550 ml of water, adjust the pH of the spray to 4.9 with an appropriate amount of citric acid / sodium citrate, add water to make the volume to 1000 ml, and prepare a colorless and clear flumazenil nasal spray.
[0105] Example 6 Preparation of flumazenil nasal spray of the present invention
[0106] Flumazenil nasal spray composition:
[0107]
[0108]
[0109] The preparation of flumazenil nasal spray comprises the following steps:
[0110] After uniformly mixing the required amounts of benzyl alcohol, polyethylene glycol 400, and benzalkonium chloride, add the required amount of flumazenil, stir until dissolved, add 650 ml of water, then add the required amount of benzalkonium chloride, adjust the pH of the spray to 5.0 with an appropriate amount of citric acid / sodium citrate, add water to make the volume to 1000 ml, and prepare a colorless and clear flumazenil nasal spray.
[0111] Example 7 Preparation of flumazenil nasal spray of the present invention
[0112] Flumazenil nasal spray composition:
[0113] Components Dosage(g) Flumazenil 2.0 Benzyl alcohol 45.0 Propylene glycol 50.0 Polyethylene glycol 400 200.0
[0114] The preparation of flumazenil nasal spray comprises the following steps:
[0115] After uniformly mixing the required amount of benzyl alcohol, propylene glycol, and polyethylene glycol 400, add the required amount of flumazenil, stir until dissolved, add 600 ml of water, adjust the pH of the spray to 4.0 with an appropriate amount of citric acid / sodium citrate, add water to make the volume to 1000 ml, and prepare a colorless and clear flumazenil nasal spray.
[0116] Example 8 Preparation of flumazenil nasal spray of the present invention
[0117] Flumazenil nasal spray composition:
[0118]
[0119]
[0120] The preparation of flumazenil nasal spray comprises the following steps:
[0121] After uniformly mixing the required amount of benzyl alcohol and polyethylene glycol 400, add the required amount of flumazenil, stir until dissolved, add 650 ml of water, adjust the pH of the spray to 3.5 with an appropriate amount of citric acid / sodium citrate, add water to make the volume to 1000 ml, and prepare a colorless and clear flumazenil nasal spray.
[0122] Example 9 Preparation of flumazenil nasal spray of the present invention
[0123] Flumazenil nasal spray composition:
[0124] Components Dosage(g) Flumazenil 2.0 Benzyl alcohol 50.0 Polyethylene glycol 400 100.0
[0125] The preparation of flumazenil nasal spray comprises the following steps:
[0126] After uniformly mixing the required amount of benzyl alcohol and polyethylene glycol 400, add the required amount of flumazenil, stir until dissolved, add 700 ml of water, adjust the pH of the spray to 4.0 with an appropriate amount of citric acid / sodium citrate, add water to make the volume to 1000 ml, and prepare a colorless and clear flumazenil nasal spray.
[0127] Example 10 Preparation of Flumazenil Nasal Spray
[0128] Flumazenil nasal spray composition:
[0129]
[0130]
[0131] The preparation of flumazenil nasal spray comprises the following steps:
[0132] After uniformly mixing the required amount of benzyl alcohol and polyethylene glycol 400, add the required amount of flumazenil, stir until dissolved, add 700 ml of water, adjust the pH of the spray to 4.5 with an appropriate amount of citric acid / sodium citrate, add water to make the volume to 1000 ml, and prepare a colorless and clear flumazenil nasal spray.
[0133] Embodiment 11 Preparation of flumazenil nasal spray of the present invention
[0134] Components Dosage(g) Flumazenil 2.0 Benzyl alcohol 42.5 Propylene glycol 50.0 Polyethylene glycol 400 200.0
[0135] The preparation of flumazenil nasal spray comprises the following steps:
[0136] After uniformly mixing the required amount of benzyl alcohol, propylene glycol, and polyethylene glycol 400, add the required amount of flumazenil, stir until dissolved, add 600 mL of water, adjust the pH of the spray to 4.0 with an appropriate amount of citric acid / sodium citrate, add water to make the volume to 1000 ml, and prepare a colorless and clear flumazenil nasal spray.
[0137] Example 12 Preparation of flumazenil nasal spray of the present invention
[0138] Preparation of Flumazenil Nasal Spray:
[0139]
[0140]
[0141] The preparation of flumazenil nasal spray comprises the following steps:
[0142] After uniformly mixing the required amount of benzyl alcohol, propylene glycol, and polyethylene glycol 400, add the required amount of flumazenil, stir until dissolved, add 550 mL of water, adjust the pH of the spray to 4.5 with an appropriate amount of citric acid / sodium citrate, add water to make the volume to 1000 mL, and prepare a colorless and clear flumazenil nasal spray.
[0143] Example 13 Preparation of flumazenil nasal spray of the present invention
[0144] Flumazenil nasal spray composition:
[0145] Components Dosage(g) Flumazenil 2.0 Benzyl alcohol 55.0 Propylene glycol 50.0 Polyethylene glycol 400 200.0
[0146] The preparation of flumazenil nasal spray comprises the following steps:
[0147] After uniformly mixing the required amount of benzyl alcohol, propylene glycol, and polyethylene glycol 400, add the required amount of flumazenil, stir until dissolved, add 500 mL of water, adjust the pH of the spray to 4.5 with an appropriate amount of citric acid / sodium citrate, add water to make the volume to 1000 mL, and prepare a colorless and clear flumazenil nasal spray.
[0148] Embodiment 14 Preparation of flumazenil nasal spray of the present invention
[0149] Flumazenil nasal spray composition:
[0150] Components Dosage(g) Flumazenil 2.0 Benzyl alcohol 60.0 Propylene glycol 50.0 Polyethylene glycol 400 200.0
[0151] The preparation of flumazenil nasal spray comprises the following steps:
[0152] After the required amount of benzyl alcohol, propylene glycol, and polyethylene glycol 400 are uniformly mixed, the required amount of flumazenil is added, and the mixture is stirred until dissolved. Then, 550 mL of water is added, and then an appropriate amount of citric acid / sodium citrate is added to adjust the pH of the spray to 5.0. Water is added to make the volume to 1000 mL to prepare a colorless and clear flumazenil nasal spray.
[0153] Embodiment 15 Preparation of flumazenil nasal spray of the present invention
[0154] Flumazenil nasal spray composition:
[0155] Components Dosage(g) Flumazenil 2.0 Benzyl alcohol 45.0 Propylene glycol 50.0 Polyethylene glycol 400 200.0
[0156] The preparation of flumazenil nasal spray comprises the following steps:
[0157] After the required amount of benzyl alcohol, propylene glycol, and polyethylene glycol 400 are uniformly mixed, the required amount of flumazenil is added, stirred until dissolved, 480 mL of water is added, and then an appropriate amount of citric acid / sodium citrate is added to adjust the pH of the spray to 4.5, and water is added to make the volume to 1000 ml to prepare a colorless and clear flumazenil nasal spray.
[0158] Test Example 1 Investigation of the ciliary toxicity of the flumazenil nasal spray of the present invention
[0159] Taking the flumazenil nasal spray prepared in Examples 1-4 as examples, the ciliary toxicity of the flumazenil nasal spray prepared in the present invention was investigated.
[0160] Taking bullfrog as animal model, after the spinal cord is destroyed, the oral palate mucosa is taken, blood clots and dirt are washed off, and the mucosa is divided into 3mm×3mm, with the cilia facing upward, and physiological saline is added as a negative control, 1% sodium deoxycholate is added as a positive control, and 100 μL of flumazenil nasal spray prepared in Examples 1-4 is added respectively. Each group is paralleled 3 times, and the movement of cilia is observed under a microscope. After observation, it is placed in a culture dish containing water, sealed, and taken out for observation at appropriate intervals. If it continues to swing, it is placed back in the culture dish after observation, and the swing start time and the swing stop time are recorded. The time difference between the swing start time and the swing stop time is the ciliary continuous motion time (LTCM). If it is observed that the cilia stop swinging, the cover glass is clamped with tweezers, the cilia are rinsed with physiological saline, and then placed under an optical microscope to observe whether the swing of the mucociliary can be restored. If the swing can be restored, the recovery swing time is recorded, and the LTCM is the sum of the continuous motion time and the recovery swing time.
[0161] The relative percentage of ciliary motion (PPV) = test sample LTCM / negative control sample LTCM. The results are shown in Table 3.
[0162] Table 3
[0163]
[0164]
[0165] As can be seen from Table 1, the mucosal surface of the flumazenil nasal spray exemplified by Examples 1-4 of the present invention is intact, the relative percentage of ciliary movement is high, no ciliary toxicity is shown, and the safety and effectiveness are excellent.
[0166] Test Example 2 Study on the nasal mucosal irritation effect of the flumazenil nasal spray of the present invention
[0167] Taking the flumazenil nasal spray prepared in Example 2 and Example 4 as examples, the irritation effect of the flumazenil nasal spray of the present invention on the nasal mucosa of rats after continuous administration for 5 days and one week of drug withdrawal was investigated.
[0168] 200-250g male and female SD rats were randomly divided into 6 groups, 3 rats in each group, and divided into normal saline group, 1% sodium deoxycholate group, Example 4 group and its recovery group, Example 2 group and its recovery group. The experimental animals were continuously administered 50 μL per nostril for 5 days. Except for the recovery group, which was sampled one week after drug withdrawal, the other groups were sampled within 24 hours. The results are shown in Table 1. Figure 1 .
[0169] Compared with the saline group, the cilia of the nasal spray of Example 2 were shorter, and the epithelial cells showed inflammatory infiltration and were slightly swollen. After recovery after one week of drug withdrawal, the cilia structure was clear and complete; the cilia of the nasal spray of Example 4 were dense, goblet cells were obvious, and there was no obvious inflammatory cell infiltration. After recovery after one week of drug withdrawal, the cilia structure was still dense and clear.
[0170] Test Example 3 Study on the stability of the flumazenil nasal spray of the present invention
[0171] Taking the flumazenil nasal spray prepared in Example 4 as an example, its stability at pH 3.5, pH 4.0, pH 4.5, pH 5.0, pH 5.5, and pH 6.0 was investigated. It was placed in a 2mL ampoule bottle, and then placed at 60°C, 40°C, 25°C, strong light irradiation (4500 ± 500) lx and dark conditions for 5 days, 10 days, and 30 days. After sampling respectively, its properties were observed, pH, drug content, and related substances were detected, and the results are shown in Table 4. Flumazenil nasal spray of the present invention has good stability.
[0172] Table 4
[0173]
[0174]
[0175]
[0176]
[0177] The above-described embodiments are only preferred embodiments for fully illustrating the present invention, and the protection scope of the present invention is not limited thereto. Equivalent substitutions or changes made by those skilled in the art based on the present invention are within the protection scope of the present invention. The protection scope of the present invention shall be subject to the claims.
Claims
1. A flumazenil nasal spray, which contains 0.1-1% flumazenil, 1-20% benzyl alcohol, 0-20% propylene glycol and 20% polyethylene glycol 4000 in a mass-volume ratio.
2. The nasal spray according to claim 1, wherein the nasal spray contains 0.1-0.5% flumazenil, 4-10% benzyl alcohol, 0-10% propylene glycol and 10-20% polyethylene glycol 400 in a mass-volume ratio.
3. The nasal spray according to claim 1, wherein the nasal spray contains 0.1-0.5% flumazenil, 4-10% benzyl alcohol, 5-10% propylene glycol and 10-20% polyethylene glycol 400 in a mass-volume ratio.
4. The nasal spray according to any one of claims 1 to 2, wherein the mass ratio of benzyl alcohol:propylene glycol:polyethylene glycol 400 in the nasal spray is 1-20:0-20:0-20, preferably 4-10:0-10:10-20, and more preferably 4-10:5-10:10-20.
5. The nasal spray according to any one of claims 1 to 3, further comprising an acid-base regulator, preferably, the acid-base regulator is selected from hydrochloric acid, sodium hydroxide, citric acid, sodium citrate, malate, lactic acid, sodium lactate, potassium lactate, triethanolamine, potassium carbonate, potassium bicarbonate, sodium carbonate, sodium bicarbonate, phosphate, sodium phosphate, disodium hydrogen phosphate, sodium dihydrogen phosphate, potassium phosphate, dipotassium hydrogen phosphate, potassium dihydrogen phosphate, HAc (acetic acid) / NaAc (sodium acetate), citric acid / sodium citrate, NaHCO 3 / H 2 CO 3 、Na 2 HPO 4 / NaH 2 PO 4 Any one or combination of .
6. The nasal spray according to any one of claims 1 to 5, wherein the pH of the nasal spray is 3.5-6.0, preferably pH 4.0-5.
5.
7. The nasal spray according to any one of claims 1 to 6, optionally containing a preservative, preferably, the preservative is selected from any one of benzalkonium bromide, benzoic acid, sodium benzoate, methylparaben, ethylparaben, propylparaben, butylparaben, sorbic acid, ethanol, glycerol, phenol, cresol, chlorobutanol or a combination thereof.
8. The flumazenil nasal spray according to any one of claims 1 to 7, wherein the preparation method is selected from any one of method 1 or method 2: Method 1: Weigh the required amount of benzyl alcohol, propylene glycol and polyethylene glycol 400, mix them evenly, then add the required amount of flumazenil, and after it is completely dissolved, add water to 60-90% of the spray, mix evenly, adjust the pH of the system to 3.5-6.0 with an acid-base regulator, and add water to the fixed volume to obtain the product; Method 2: Weigh the required amount of benzyl alcohol, propylene glycol and polyethylene glycol 400, mix them evenly, add water to 60-90% of the spray, mix them evenly, then add the required amount of flumazenil, stir until completely dissolved, adjust the system pH to 3.5-6.0 with an acid-base regulator, add water to make up to volume, and you have it.
9. The method for preparing the flumazenil nasal spray according to any one of claims 1 to 8, wherein the nasal spray contains 0.1-1% flumazenil, 1-20% benzyl alcohol, 0-20% propylene glycol and 0-20% polyethylene glycol 400 in terms of mass volume ratio, and the preparation method is selected from any one of method 1 or method 2: Method 1: Weigh the required amount of benzyl alcohol, propylene glycol and polyethylene glycol 400, mix them evenly, then add the required amount of flumazenil, and after it is completely dissolved, add water to 60-90% of the spray, mix evenly, adjust the pH of the system to 3.5-6.0 with an acid-base regulator, and add water to the fixed volume to obtain the product; Method 2: Weigh the required amount of benzyl alcohol, propylene glycol and polyethylene glycol 400, mix them evenly, add water to 60-90% of the spray, mix them evenly, then add the required amount of flumazenil, stir until completely dissolved, adjust the system pH to 3.5-6.0 with an acid-base regulator, add water to make up to volume, and you have it.
10. The flumazenil nasal spray according to any one of claims 1 to 8 is used for the preparation of a nasal spray for reversing benzodiazepines in adults or children aged 1 year and above Application of drugs in the treatment of central nervous system sedation, hypnosis and overdose poisoning caused by these drugs.
Citation Information
Patent Citations
Administration of benzodiazepine
CN107737100A
Alprazolam nasal spray
CN1303674A
Method of controlling alcohol intake and reversing alcohol effects
US20060263304A1
Pharmaceutical preparation and delivery system
US20120122851A1
Pharmaceutical Preparations Of Melatonin Suitable For Intranasal Administration
US20230143212A1
